Is Altamira Therapeutics Ltd. (CYTO) a Buy, Sell, or Hold?
NASDAQ : CYTO
Altamira Therapeutics Ltd.
$0.3 USD
$0.3 (0%)
- Volume
- 724.3K
- Average Volume
- 244.02K
- Market Capitalization
- $1.13M
- P/E Ratio
- -0.02
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.42
- Year Low
- $0.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.32
Company Overview
NASDAQ
Thomas Meyer
Biotechnology
Healthcare
CYTO
10
BM
USD
Liquidity Metrics
0.05
1.32
1.32
0.86
0.00
Sales & Valuation
-$
0.00
0.02
-0.18
-12.66
Profitability
-$14.8
-$7.27M
0.00%
0.00%
-111.64%
-84.03%
P/E Metrics
-0.02
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-1.16
4/9
$376.22K
$8.65M
$2.09M
-$2.61M
Key Metrics (TTM)
$495.98K
0.00
-0.09
1.32
-111.64%
-77.74%
-4935.51%
-548.42%
-1687 days
Company Executives
| Name | Title |
|---|---|
| Samuel A. Wickline | Chief Scientific Adviser |
| Thomas Meyer | Founder, President, Chairman, Chief Executive Officer & MD |
| Covadonga Paneda | Chief Operating Officer |
| Marcel Gremaud | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Altamira Therapeutics Ltd. (NASDAQ:CYTO) Stock
Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi ... addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.
Frequently Asked Questions
-
What is the current Altamira Therapeutics Ltd. (CYTO) stock price?
-
Altamira Therapeutics Ltd.(NASDAQ:CYTO) stock price is $0.3 in the last trading session. During the trading session, CYTO stock reached the peak price of $0.4158 while $0.3 was the lowest point it dropped to. The percentage change in CYTO stock occurred in the recent session was 0% while the dollar amount for the price change in CYTO stock was $0.3.
-
CYTO's industry and sector of operation?
-
The NASDAQ listed CYTO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CYTO?
-
Samuel A. Wickline | Chief Scientific Adviser
Thomas Meyer | Founder, President, Chairman, Chief Executive Officer & MD
Covadonga Paneda | Chief Operating Officer
Marcel Gremaud | Chief Financial Officer
| -
How many employees does CYTO have?
-
Number of CYTO employees currently stands at 10. CYTO operates from Clarendon House, Hamilton, None HM 11, BM.
-
Link for CYTO official website?
-
Official Website of CYTO is: https://altamiratx.com
-
How do I contact CYTO?
-
CYTO could be contacted at phone #441 295 5950 and can also be accessed through its website. CYTO operates from Clarendon House, Hamilton, None HM 11, BM.
-
How many shares of CYTO are traded daily?
-
The average number of CYTO shares traded daily for last 3 months was 244.02K.
-
What is the market cap of CYTO currently?
-
The market value of CYTO currently stands at $1.13M with its latest stock price at $0.3